Skip to main content
OpenTrials

Clinical trial condition

Colonic Diseases

Explore clinical trials studying Colonic Diseases. Study availability and eligibility vary by location and protocol.

7,535 public trials 1,488 recruiting studies
Refine in advanced search Browse all conditions

Colonic Diseases trial results

Completed

DNA Evaluation of Fragments for Early Interception - Lung Cancer Training Study (DELFI-L101 Study)

NCT04825834

Conditions
Bladder Cancer, Colonic Diseases, Colorectal Cancer, +48 more
Locations
  • Central Alabama Research Homewood, Alabama, United States
  • Phoenix Medical Group Peoria, Arizona, United States
  • Highlands Oncology Group - Fayetteville Fayetteville, Arkansas, United States
  • Pulmonary Associates of Burlingame Burlingame, California, United States
View all 57 locations
View Trial Details
Completed

Phase 1, First-in-human, Dose-finding and Expansion Study to Evaluate XmAb®808 in Combination With Pembrolizumab in Advanced Solid Tumors

NCT05585034

Conditions
Adenocarcinoma, Adnexal Diseases, Breast Diseases, +58 more
Locations
  • UCLA Hematology/Oncology Los Angeles, California, United States
  • Sarah Cannon Research Institute at HealthONE Denver, Colorado, United States
  • Florida Cancer Specialists Sarasota, Florida, United States
  • Winship Cancer Institute, Emory University Atlanta, Georgia, United States
View Trial Details
Completed

Optimal Peripheral Nerve Block After Minimally Invasive Colon Surgery

NCT04311099

Conditions
Abdominal Pain, Agnosia, Analgesia, +26 more
Locations
  • Sydvestjysk Sygehus Esbjerg, Denmark
  • Regionshospitalet Herning Herning, Denmark
  • Copenhagen University Hospital - North Zealand Hillerød, Denmark
  • Copenhagen University Hospital - Hvidovre Hvidovre, Denmark
View Trial Details
Completed

A Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Moderately to Severely Active Ulcerative Colitis (MK-7240-005)

NCT04996797

Conditions
Colitis, Colitis, Ulcerative, Colonic Diseases, +7 more
Locations
  • Prometheus Biosciences Selected Center Mobile, Alabama, United States
  • Prometheus Biosciences Selected Site Phoenix, Arizona, United States
  • Prometheus Biosciences Selected Site Sun City, Arizona, United States
  • Prometheus Biosciences Selected Site Los Angeles, California, United States
View all 88 locations
View Trial Details
Completed

Arginase Inhibitor INCB001158 as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors

NCT02903914

Conditions
Adenocarcinoma, Adenoma, Bladder Cancer, +49 more
Locations
  • University of South Alabama Mobile, Alabama, United States
  • Honor Health/Pinnacle Oncology Hematology Scottsdale, Arizona, United States
  • University of Arizona Tucson, Arizona, United States
  • Georgetown Washington D.C., District of Columbia, United States
View all 20 locations
View Trial Details

Related conditions